By Andrew Weil, M.D. Provided by: DrWeil.com

Dr. Weil's Healthy Living

Be Cautious About Chelation Posted Tue, Oct 23, 2007, 3:46 pm PDT

46% of users found this article helpful.

In 2005, the FDA approved the drug deferasirox (Exjade), an oral chelating agent for treating chronic iron overload due to multiple blood transfusions.

Until then, the only way to treat iron overload was with daily prolonged intravenous therapy. Chelating agents grab metal atoms, forming complexes that can be excreted in the urine. Their use is standard treatment for heavy metal poisoning. Many popular but unproven and unapproved "alternative therapies" for cardiovascular disease, multiple sclerosis, and other chronic conditions claim to use the process of chelation.

It would be convenient to have a safe and effective orally active chelating agent, especially for iron. However, on May 22, 2007, the FDA and the drug manufacturer, Novartis, warned doctors that Exjade has been associated with some cases of kidney failure and other serious medical complications, some of which were fatal. Most of the patients involved had advanced, pre-existing blood disorders; a few had bone marrow failure.

I'm aware that various oral chelating agents are promoted on the Internet for everything from removing mercury from the body to treating chronic fatigue syndrome. There is no scientific evidence for the effectiveness of these products. Intravenous chelation therapy (with a compound called EDTA) is effective, but will do nothing for diseases unrelated to toxic metals in the body. I was recently asked, for example, whether IV chelation could be useful against multiple sclerosis. The answer is no: because MS does not have an association with toxic metals, chelation therapy is not indicated for it.

By the way, I've always been skeptical of claims that IV chelation effectively removes plaque from arteries (supposedly by extracting calcium from it). This issue may finally be settled when the National Center for Complementary and Alternative Medicine completes a five-year, $30 million study of EDTA chelation therapy in patients with heart disease.

The study, called TACT (Trial to Assess Chelation Therapy), is recruiting volunteers and will conclude in 2009.

- - - - - - - - - - - - - - - - - - - - - -  

  

More from Dr. Weil:

Sign up for Dr. Weil's Daily Tip.

Confused About Vitamins? Visit the Vitamin Advisor and get Dr. Weil's free recommendation today.

Aging Gracefully, Simply. Find simple steps to a lifetime of health on Dr. Weil on Healthy Aging.

Submit your question to the Ask Dr. Weil today.

Was this blog entry helpful?
Tell us what you think.

Rate this blog entry:
liked it no thanks

Leave Your Comment

Comment Guidelines You must sign in to post a comment

Yahoo! Health Videos

My Health

help

Tip of the Day

Provided by: RealAge

Straight out of the can, peanuts are one amazing health food. But you may get more antioxidants if you buy them in the shell and do this: boil 'em. Read More »

View All Tips »

Tell us what you think about Yahoo! Health - Send us your feedback